Abstract Library

#3053 The Splicing Machinery Is Dysregulated in Low Grade Pulmonary Neuroendocrine Tumors

Introduction: Alternative splicing dysregulation is increasingly regarded as a novel cancer hallmark influencing all key tumor features. We have shown that neuroendocrine tumors (NETs) overexpress aberrantly spliced variants of neuropeptides and receptors that increase tumor malignancy. More recently, we discovered that the splicing machinery is dysregulated in pituitary and pancreatic NETs. To date, the status of this machinery in low grade pulmonary NETs is largely unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Blázquez-Encinas R

Authors: Blázquez-Encinas R, Caro M, Pedraza-Arévalo S, Alors-Pérez E, Herrera-Martínez A,

Keywords: low grade pulmonary NETs, splicing, splicing machinery, malignancy,

#3014 The Number of Positive Nodes Accurately Predicts Recurrence after Distal Pancreatectomy for Nonfunctioning Neuroendocrine Neoplasms

Introduction: The most appropriate staging system of metastatic lymph nodes (N) for resected pancreatic neuroendocrine tumors (PanNETs) remains unclear, especially regarding those resected by distal pancreatectomy (DP).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Guarneri G

Authors: Guarneri G, de Mestier L, Partelli S, Landoni L, Gaujoux S,

Keywords: non-functioning pancreatic neuroendocrine neoplasm, distal pancreatectomy, examined lymph-node,

#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers

Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Merkel C

Authors: Merkel C, Whicher C, Herrmann K, Jervis N, Ćwikła J,

Keywords: PRRT, peptide receptor radionuclide therapy, radioligand therapy, policy, multidisciplinary care, nuclear medicine, neuroendocrine cancer,

#2939 Prognostic Evaluation for Gastroenteropancreatic NEC: AJCC or ENETS Staging Classification or Others?

Introduction: For poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), American Joint Committee on Cancer (AJCC) recommends to use a classification different from that for well-differentiated neuroendocrine tumor. However, this is not adopted by European Neuroendocrine Tumor Society (ENETS) staging classification.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Chen L, Lin Z, Zhang T, Chen M,

Keywords: gastroenteropancreatic neuroendocrine carcinoma, prognosis, staging,

#2923 Interim Analysis of Prospective Evaluation of the Management of Sporadic Nonfunctioning Asymptomatic Pancreatic Neuroendocrine Neoplasms ≤ 2 cm (ASPEN Study)

Introduction: Guidelines recommend a watchful strategy for small, incidental, nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNEN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Partelli S

Authors: Partelli S, Zerbi A, Massironi S, Jin-Young J, Landoni L,

Keywords: small neuroendocrine pancreatic tumors, surveillance, surgery, follow-up,